In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celsion plunges on Phase III failure for ThermoDox in HCC

This article was originally published in Clinica

Executive Summary

Celsion president and CEO Michael Tardugno offered investors few details during a 31 January conference call about how poorly the company's ThermoDox technology performed in the Phase III HEAT clinical trial in hepatocellular carcinoma (HCC), but the few insights he offered were painful to hear, especially for investors who saw Celsion's stock close down 81.2%.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts